Optimising malignant melanoma management in Europe
EUMelaReg collects health information to improve care and treatment for patients with skin cancer
Sustaining and fostering collaboration between academia and industry
for the collection of baseline, treatment and outcome data of representative samples of malignant melanoma patients of major European countries.
Building the largest and quickest melanoma registry in the world
EUMelaReg collects real-world data on melanoma patients throughout Europe and integrates them in a data warehouse.

EUMelaReg ADJU-SEQ poster presented at ESMO congress 2023

As part of the EUMelaReg ADJU-SEQ project a subanalysis was performed and accepted for poster presentation at the ESMO Congress 2023 in Madrid (Abstract title: Efficacy of immune checkpoint inhibition in metastatic or non-resectable melanoma after failure of adjuvant anti-PD1 treatment. A EUMelaReg real-world evidence study.). The study was successfully presented on Sunday, October 22nd, 2023 by Professor Michael Weichenthal. The poster received a lot of attention from the congress participants and the presentation was very well attended. The topic and the results were met with interest by the specialist audience. Subsequent questions and discusssions facilitated a lively professional exchange.